Article
Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer.
European urology - 1 Jan 2023
Truong Hong, Breen Kelsey, Nandakumar Subhiksha, Sjoberg Daniel D, Kemel Yelena, Mehta Nikita, Lenis Andrew T, Reisz Peter A, Carruthers Jessica, Benfante Nicole, Joseph Vijai, Khurram Aliya, Gopalan Anuradha, Fine Samson W, Reuter Victor E, Vickers Andrew J, Birsoy Ozge, Liu Ying, Walsh Michael, Latham Alicia, Mandelker Diana, Stadler Zsofia K, Pietzak Eugene, Ehdaie Behfar, Touijer Karim A, Laudone Vincent P, Slovin Susan F, Autio Karen A, Danila Daniel C, Rathkopf Dana E, Eastham James A, Chen Yu, Morris Michael J, Offit Kenneth, Solit David B, Scher Howard I, Abida Wassim, Robson Mark E, Carlo Maria I
Abstract excerpt
BACKGROUND: Tumor-only genomic profiling is an important tool in therapeutic management of men with prostate cancer. Since clinically actionable germline variants may be reflected in tumor profiling, it is critical to identify which variants have a higher risk of being germline in origin to better counsel patients and prioritize genetic testing. OBJECTIVE: To determine when variants found on tumor-only sequencing...
Topics
- Male
- Humans
- Germ-Line Mutation
- Prostatic Neoplasms
- Genetic Testing
- Sequence Analysis
- Genomics